Cipla Ltd (CIPL.NS) Key Developments |
United States

Cipla Ltd (CIPL.NS)

CIPL.NS on National Stock Exchange of India

6:21am EDT
Change (% chg)

Rs7.60 (+1.52%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Cipla appoints Kedar Upadhye as global CFO
Wednesday, 8 Jun 2016 03:54am EDT 

Cipla Ltd : Approved the appointment of Kedar Upadhye as global chief financial officer of the company . Umang Vohra will cease to be the global chief financial officer of the company . Vohra will continue to be the global chief operating officer .  Full Article

Cipla says co expects EBITDA growth of 15-20 pct in fiscal 2017
Tuesday, 24 May 2016 09:33am EDT 

Cipla Ltd : Says plans to file for approval of 20 to 25 products in U.S. in fiscal 2017 . Says looking to exit some businesses in emerging markets "due to complexities involved" . Says Q4 impacted by inventory and job cuts related provisions in Europe, emerging markets . Says expects EBITDA growth of 15-20 percent in fiscal 2017 . Further company coverage [CIPL.NS] ((Bengaluru Newsroom; +91 80 6749 1130)).  Full Article

Cipla Ltd March-qtr consol profit down about 69 pct
Tuesday, 24 May 2016 08:32am EDT 

Cipla Ltd : India's Cipla Ltd says March-quarter consol net profit 808.7 million rupees; consol net sales 32.07 billion rupees . India's Cipla Ltd consensus forecast for March-quarter net profit was 3.79 billion rupees . Recommended dividend of 2 rupees per share .  Full Article

Cipla Ltd Partners with Serum Institute India (SII) to Provide Vaccines in South Africa
Thursday, 8 Oct 2015 04:47am EDT 

Cipla Ltd:Announces Partners with Serum Institute India (SII) to Provide Vaccines in South Africa.  Full Article

Cipla to acquire 100 pct of generic businesses in US for $550M
Thursday, 3 Sep 2015 11:39pm EDT 

Cipla Ltd:Says Cipla EU has entered into definitive agreements to acquire two US-based companies, InvaGen Pharmaceuticals Inc., and Exelan Pharmaceuticals Inc.The transaction being subject to certain closing conditions, is valued at $550 million and will be an all cash transaction.The combined revenue from these transactions is over $200 million for the year ended Dec 2014 and over $225 million in LTM June 2015.  Full Article

Cipla Ltd announces an investment led by Fidelity Growth Partners India into the newly launched Consumer Healthcare business
Tuesday, 21 Jul 2015 09:32am EDT 

Cipla Ltd:Says has approved investmen by Fidelity Growth Partners India and US based Fidelity Biosciences, through FIL Capital Investments II Ltd or its affiliates in its recently launched consumer healthcare business which is under incorporation.  Full Article

Cipla Ltd and Bristol-Myers Squibb settles patent dispute - Business Standard
Tuesday, 16 Jun 2015 08:00pm EDT 

Cipla Ltd:Says patent dispute between Bristol-Myers Squibb (BMS) and Cipla over entecavir, a pharmaceutical combination for treating Hepatitis B has been settled amicably out of the court - Business Standard.Says Counsels appearing for both the parties informed the Appellate Board that the matter has been settled out of court in April, 2015.Says taking the endorsement to the registry on record, the bench comprising of IPAB Chairman Justice K N Basha and Technical Member (Patent) DPS Parmar dismissed the application as withdrawn not pressed.Says companies requested the terms of settlement has to be kept confidential.  Full Article

Cipla Ltd receives Japan process patent for its novel stem cell drug 'Stempeucel'
Monday, 8 Jun 2015 02:41am EDT 

Cipla Ltd:Announces that it has been granted process patent from the Japan Patent Office (application no 2012-540529) for its novel stem-cell based drug Stempeucel.Says the novelty covers the method of preparing master cell banks, working cell banks and the final therapeutic product 'Stempeucel' based on the novel pooling technology.  Full Article

Cipla Ltd says U.S. FDA approves AIDS treatment in infants and young children
Wednesday, 3 Jun 2015 06:17am EDT 

Cipla Ltd:Says U.S. FDA approval for paediatric lopinavir and ritonavir oral pellets for treatment of aids in infants and young children.Received US FDA approval for an innovative formulation — Lopinavir/ ritonavir (LPV/r) 40mg/ 10 mg oral pellets — for paediatric specific treatment for infants.  Full Article

Cipla Ltd says JV Partner gets orphan drug status in EU for stem cell drug
Monday, 1 Jun 2015 05:53am EDT 

Cipla Ltd:Says Stempeutics receives orphan drug designation in the European union for its novel stem cell drug stempeucel.  Full Article